Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference

BearDownAZ

Apr 01, 2019 11:08AM

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference

in response to

Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference

BearDownAZ

posted on Apr 01, 2019 01:29PM

Some interesting tidbits in Dr. Cummings AD/PD presentation.

"Top line data is expected the summer of 2019"

I like the sound of that.

"Average treatment duration 26 months (range 14‐36 months)"

That makes it sound like dosing ends after 3 years. Or no patients have survived past 3 years. First patient started November 2015.

"Subgroups of patients with MoCA score <26 and <21 at baseline will also be analyzed"

Nice! Another sub-group.

3 Recommendations

Re: Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference